Medscape12h
Bladder Cancer Survival Better with Nivolumab than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
'Health equity is a business imperative:' Companies work for better Black health outcomes
At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...
Medscape1d
Diet Changes Show Promise in Early Prostate Cancer
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Gilead price target raised to $120 from $105 at Bernstein
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up
We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...
Gilead’s Seladelpar granted conditional European marketing authorization
Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...
Richmond3d
Drugmakers fighting hard in Virginia to keep control of medicine prices
Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...
Healthcare sector takes the lead in 2025 as market volatility rises
The Healthcare sector of the economy is front and center on Friday as shares of UnitedHealth drop 7.8%, spurring a widespread market selloff across the broader market a ...
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79
The board of Gilead Sciences, Inc. (NASDAQ:GILD) has announced that the dividend on 28th of March will be increased to $0.79, ...
Gilead’s Seladelpar gets European Marketing Authorization for liver disease treatment
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...